Dose considerations for anti‐cancer drugs in metastatic prostate cancer
暂无分享,去创建一个
[1] F. Goldwasser,et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. , 2017, European journal of cancer.
[2] T. Yoshimura,et al. Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer. , 2016, Molecular and clinical oncology.
[3] F. Saad,et al. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). , 2016 .
[4] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[5] S. von Felten,et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. , 2016, European journal of cancer.
[6] A. Armstrong,et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] G. Sonpavde,et al. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer , 2016, Medicine.
[8] C. Kollmannsberger,et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer , 2015, Journal of clinical pharmacology.
[9] H. Scher,et al. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. , 2015, European urology.
[10] Si Sun,et al. Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen , 2015, Oncotarget.
[11] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[12] Sunjoo Ahn,et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats , 2015, Archives of pharmacal research.
[13] M. Joerger. Metabolism of the taxanes including nab-paclitaxel , 2015, Expert opinion on drug metabolism & toxicology.
[14] T. Ouatas,et al. Clinical Pharmacokinetic Studies of Enzalutamide , 2015, Clinical Pharmacokinetics.
[15] F. Saad,et al. Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America , 2015, The Prostate.
[16] F. Saad,et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.
[17] J. Richie,et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[19] S. Fosså,et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. , 2014, European journal of cancer.
[20] A. Bertaut,et al. Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. , 2014, World journal of gastroenterology.
[21] H. Scher,et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. Carles,et al. PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen. , 2013 .
[23] H. Joensuu,et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. , 2013, The Lancet. Oncology.
[24] G. Ferron,et al. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.
[25] G. Pond,et al. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. , 2012, Clinical genitourinary cancer.
[26] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[27] M. van Glabbeke,et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup , 2012, European journal of cancer.
[28] K. Matsuo,et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy , 2011, Cancer Chemotherapy and Pharmacology.
[29] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[30] J. Bernaudin,et al. Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] E. Antonarakis,et al. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer , 2011, Drug design, development and therapy.
[32] J. Verweij,et al. Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study , 2011, Clinical Cancer Research.
[33] M. Carducci,et al. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[35] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[36] P. Kantoff,et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Tsuboi,et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 , 2009, British Journal of Cancer.
[38] K. Matsuo,et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. , 2009, European journal of cancer.
[39] M. Dowsett,et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Mencoboni,et al. Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient , 2006, Chemotherapy.
[41] J. Verweij,et al. Clinical Pharmacokinetics of Docetaxel , 2006, Clinical pharmacokinetics.
[42] J. Verweij,et al. Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia , 2005, Clinical pharmacology and therapeutics.
[43] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[44] J. Verweij,et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] H. Ohmatsu,et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] H. Gurney,et al. How to calculate the dose of chemotherapy , 2002, British Journal of Cancer.
[47] Earhart Rh. Docetaxel (Taxotere): preclinical and general clinical information. , 1999, Seminars in oncology.
[48] C. Blomqvist,et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF , 1999, British Journal of Cancer.
[49] M. Ratain. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] S. Fosså,et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] H. Gurney,et al. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] H. Burris. Optimal use of docetaxel (Taxotere®): maximizing its potential , 1996, Anti-cancer drugs.
[53] D. Cruickshank,et al. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. , 1992, British Journal of Cancer.
[54] F. Saad,et al. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer , 2016, Clinical Pharmacokinetics.
[55] J. Pierga,et al. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. , 2013, European journal of cancer.
[56] Bin Zhang,et al. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer , 2011, Breast Cancer Research and Treatment.
[57] E. Antonarakis,et al. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer , 2011 .
[58] 岸田 祐介. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer : results from Japan Multinational Trial Organization LC00-03 , 2010 .
[59] L B Sheiner,et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.